SEC filings and other documents

Bipolar mania Phase 2 success and $815.4M estimated liquidity support a broad 2027 pipeline.

RAP-219 met both phase II bipolar mania endpoints, supporting planned phase III development.

RAP-219 targets major neuropsychiatric markets with novel mechanisms and pivotal trial readiness.

RAP-219 targets bipolar mania with a novel mechanism, aiming for improved efficacy and tolerability.

RAP-219 advances in bipolar mania and seizures, with a transformative long-acting injectable in development.

RAP-219 shows robust efficacy in drug-resistant epilepsy, advancing to Phase 3 with strong financial backing.

RAP-219 enters Phase 3 for seizures; Q2 net loss rises, cash runway extends to 2029.

RAP-219 delivers robust efficacy in drug-resistant epilepsy, advancing toward major market opportunities.

All director nominees and the audit firm were approved by stockholder vote.

Global phase III epilepsy trials advance with robust data and broad commercial potential.

RAP-219 shows strong efficacy in epilepsy, with phase III and LAI programs advancing.

RAP-219 achieved 90% median seizure reduction and secured $20M from a Greater China partnership.

RAP-219 shows strong efficacy in drug-resistant epilepsy, advancing toward Phase 3 trials.

RAP-219's pivotal epilepsy and bipolar trials advance with robust funding and global reach.

RAP-219 advances to global phase III after strong efficacy in focal seizures and a major China deal.

RAP-219’s novel mechanism and robust clinical data drive global Phase 3 trials and pipeline expansion.

RAP-219 delivers robust seizure reduction and pipeline expansion, backed by strong financials.

RAP-219 shows unprecedented efficacy in epilepsy, with pivotal trials and LAI formulation advancing.

RAP-219 shows robust efficacy in drug-resistant epilepsy, with expansion into major CNS indications.

RAP-219 delivered robust Phase 2a efficacy, fueling pipeline growth and global expansion.

RAP-219 achieved over 70% seizure reduction in phase II, with pivotal studies and new formulations ahead.

Lead program demonstrates robust efficacy in epilepsy, with phase 3 trials and expansion planned.